CALCULATE YOUR SIP RETURNS

Granules India Secures EU GMP Certification for Unit V Facility

Written by: Team Angel OneUpdated on: Jan 30, 2025, 2:44 PM IST
Granules India’s Unit V facility in Andhra Pradesh has received the EU GMP certificate for APIs and finished dosages after a successful audit by Hungarian authorities.
Granules India Secures EU GMP Certification for Unit V Facility
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Granules India Limited has announced that its Unit V facility, located in Anakapally, Visakhapatnam, Andhra Pradesh, has been awarded the European Union Good Manufacturing Practice (EU GMP) certificate. This certification marks a significant milestone in the company’s compliance with international pharmaceutical manufacturing standards.

Regulatory Approval from EU Authorities

The certification was granted following an audit conducted in November 2024 by the National Centre for Public Health and Pharmacy, Hungary. The EU GMP certification is a crucial regulatory requirement for exporting pharmaceutical products to European markets, ensuring that the facility meets stringent quality and safety standards.

Scope of Unit V Operations

The Unit V facility plays a key role in the company’s manufacturing capabilities, focusing on the production of both Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs). The facility is involved in manufacturing formulations for oncology and non-oncology products, broadening the company’s product portfolio in critical therapeutic areas.

Strategic Importance of EU GMP Certification

Securing an EU GMP certificate enhances Granules India’s ability to supply pharmaceutical products to European markets, demonstrating its commitment to global regulatory compliance. This certification may help the company strengthen its presence in regulated markets and explore new business opportunities in the EU pharmaceutical sector.

Financial Performance of Granules 

Granules India stated in a regulatory filing that its consolidated profit after tax decreased by 6% year-on-year to ₹118 crore for the third quarter ended 31 December 2024.

The company had reported a profit after tax of ₹126 crore during the October-December quarter of the previous financial year.

Revenue from operations declined to ₹1,138 crore in the third quarter, compared to ₹1,156 crore in the corresponding period last year.

On January 30, 2025, at 9:39 AM, Granules India shares traded at ₹554.15 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Jan 30, 2025, 2:44 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2.5 Cr+ happy customers